Disease · EFO_0009844

nightmare

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nightmare. Diseases, record EFO_0009844. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009844

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nightmare; Open Targets
Open Targets ID: EFO_0009844; Open Targets
NCI Thesaurus: C117263; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 3 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLONIDINE	CHEMBL134	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXAZOSIN	CHEMBL707	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DRONABINOL	CHEMBL465	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PRAZOSIN	CHEMBL2	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor agonist	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	1	Serotonin transporter inhibitor	Unknown	https://conductscience.org/library/genes/6532	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00202449	Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance	Not applicable	59	2012-07-12	Stress Disorders, Post-Traumatic, Sleep Disorders	PAROXETINE, PRAZOSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00393874	Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)	Not applicable	50	2016-10-24	Anxiety Disorders, Mood Disorders, Insomnia, Nightmares	PRAZOSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04448808	Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol	Phase 2	170		Posttraumatic Stress Disorder	DRONABINOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05360953	Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin	Phase 2	53		Posttraumatic Stress Disorder	CLONIDINE, DOXAZOSIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42557458	DERIVED	1	PubMed
40764082	DERIVED	1	PubMed
37147642	DERIVED	1	PubMed
22281448	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009844

GET https://conductscience.org/api/diseases/v1/EFO_0009844/drugs

API reference For AI assistants